This is an old revision of this page, as edited by DOI bot (talk | contribs) at 14:35, 23 May 2008 (Citation enhancement. IN TRIAL: please check edit and report any bugs. Any concerns? Please Contact the bot's operator.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:35, 23 May 2008 by DOI bot (talk | contribs) (Citation enhancement. IN TRIAL: please check edit and report any bugs. Any concerns? Please Contact the bot's operator.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Noradrenergic and selective serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to work by blocking presynaptic alpha-2 adrenergic receptors that normally inhibit the release of the neurotransmitters norepinephrine (noradrenaline) and serotonin. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron, Zispin, Avanza, Norset, Remergil, Axit)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.
See also
References
- Kent J (2000). "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression". Lancet. 355 (9207): 911–8. doi:10.1016/S0140-6736(99)11381-3. PMID 10752718.
- Fawcett J, Barkin R (1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". J Affect Disord. 51 (3): 267–85. doi:10.1016/S0165-0327(98)00224-9. PMID 10333982. link
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |